-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Censavudine in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Censavudine in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Censavudine in Frontotemporal Dementia (FTD) Drug Details: Censavudine (Festinavir, BMS-986001,OBP-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Latozinemab in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Latozinemab in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Latozinemab in Frontotemporal Dementia (FTD) Drug Details: latozinemab is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBFT-02 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBFT-02 in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBFT-02 in Frontotemporal Dementia (FTD) Drug Details: PBFT-02 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VRG-50635 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VRG-50635 in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VRG-50635 in Frontotemporal Dementia (FTD) Drug Details: VRG-50635 is under...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rotigotine ER in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rotigotine ER in Frontotemporal Dementia (FTD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rotigotine ER in Frontotemporal Dementia (FTD) Drug Details: Rotigotine (Neupro,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VES-001 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VES-001 in Frontotemporal Dementia (FTD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VES-001 in Frontotemporal Dementia (FTD) Drug Details: VES-001 is under development...
-
Product Insights
NewProgranulin – Drugs In Development, 2024
The Progranulin pipeline drugs market research report outlays comprehensive information on the Progranulin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, and Oncology which include indications of Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis, Ovarian Cancer, and Non-Small Cell Lung Cancer. It also reviews key players involved in Progranulin targeted therapeutics development with respective active...
-
Product Insights
NewGuanine Nucleotide Exchange C9orf72 – Drugs In Development, 2024
The Guanine Nucleotide Exchange C9orf72 pipeline drugs market research report outlays comprehensive information on the Guanine Nucleotide Exchange C9orf72 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System which include indications of Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia (FTD). It also reviews key players involved in Guanine Nucleotide Exchange C9orf72 targeted therapeutics development with respective...
-
Product Insights
NewSortilin – Drugs In Development, 2024
The Sortilin pipeline drugs market research report outlays comprehensive information on the Sortilin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Oncology, and Metabolic Disorders which include indications of Frontotemporal Dementia (FTD), Alzheimer's Disease, Breast Cancer, Melanoma, and Hypercholesterolemia. It also reviews key players involved in Sortilin targeted therapeutics development with respective active and...